Eurobio Scientific expands its range of COVID-19 tests with an antigenic rapid test
18 Gennaio 2021 - 05:45PM
Eurobio Scientific expands its range of COVID-19 tests with an
antigenic rapid test
Eurobio Scientific expands its range of
COVID-19 tests with an antigenic rapid test
The
full range of tests is now referenced by the French
AdministrationNew variants of the virus remain
detected by PCR tests
Paris, January 18, 2021 – 5:45
pm
Eurobio Scientific
(FR0013240934, ALERS, PEA-PME eligible), a leading French group in
in vitro medical diagnostics and life-sciences, today announces
that its entire range of COVID-19 tests, that includes its new
proprietary antigenic test for the detection of the SARS-CoV-2
antigen, is now fully referenced on the official website of the
French Administration1.
Eurobio Scientific is thus offering one of the
most comprehensive global range of SARS-CoV-2 tests, aware of the
public health and economic challenges represented by the current
wave of the COVID-19 epidemic, while the vaccination campaign is
being initiated.
Immunochromatography-based single-use
testsThe new CE marked proprietary EBS 10-20 Ag Test
allows the detection of the SARS-Cov-2 antigen using a
nasopharyngeal swab. The result is obtained in 10 minutes. Its
implementation is easier than that of competing tests, pre-filled
reagent tubes avoiding a delicate preparation step. In addition,
particularly ergonomic swabs have been chosen to improve patient
comfort during sampling.This test is on the list of tests approved
by the health authorities for marketing in France. Its very good
performance (95% sensitivity and 99% specificity) ensures results
that meet expectations for this type of test.
Eurobio Scientific has entered into a first
partnership with NIO Pharma for the specific distribution of this
test in pharmacies in France.NIO Pharma is a French company
specializing in the distribution of digital solutions and products
for pharmacies. It markets a large catalog of pharmaceutical and
derivative products intended for French pharmacists.
PCR test performanceThe genes
targeted with all Eurobio Scientific PCR tests were specifically
chosen to be very stable, and thus mutate less than other genes, as
is notably the case in the current variants of the SARS-CoV-2 virus
(British, South African and Brazilian-Japanese variants). Thus,
thanks to the increased resilience of these tests, variants of the
virus remain perfectly detected.Eurobio Scientific's PCR tests
therefore retain their full performance in the presence of many
variants, in particular the British one which is currently
spreading in the United Kingdom and in Europe.
A range of serological tests ready to
support the vaccination campaignEurobio Scientific's range
of serological tests includes rapid unit tests, automated
laboratory tests, and seroneutralization tests2, different from
standard antibody tests, which measure the ability of a patient's
antibodies to neutralize the virus. These tests make it possible to
verify that vaccinated patients do indeed benefit from protective
immunity against COVID-19.With this particularly comprehensive
serology offering, Eurobio Scientific is ready to contribute to the
effectiveness of the vaccination campaign.
Next financial meeting2020 Sales: January 25,
2021
About Eurobio Scientific
Eurobio Scientific is a key player in the field of specialty in
vitro diagnostics. It is involved from research to manufacturing
and commercialization of diagnostic tests in the fields of
transplantation, immunology and infectious diseases, and sells
instruments and products for research laboratories, including
biotechnology and pharmaceutical companies. Through many
partnerships and a strong presence in hospitals, Eurobio Scientific
has established its own distribution network and a portfolio of
proprietary products in the molecular biology field. The Group has
approximately 148 employees and three production units based in the
Paris region, in Germany and in the United States, and several
affiliates based in Dorking UK, Sissach Switzerland, Bünde Germany
and Utrecht in The Netherlands. For more information, please
visit : www.eurobio-scientific.com The company is publicly
listed on the Euronext Growth market in Paris Euronext Growth BPI
Innovation, PEA-PME 150 and Next Biotech indices, Euronext European
Rising Tech label. Symbol: ALERS - ISIN Code: FR0013240934 -
Reuters: ALERS.PA - Bloomberg: ALERS:FP |
Contacts |
Group Eurobio Scientific Denis Fortier, General
Manager Hervé Duchesne de Lamotte, General Manager Tel. +33(0) 1 69
79 64 80 |
Calyptus Mathieu Calleux / Gregory Bosson
Investors relations Tel. +33(1) 53 65 68 68
eurobio-scientific@calyptus.net |
Disclaimer
This press release contains non-factual
elements, including, but not limited to, certain statements
regarding future results and other future events. These statements
are based on the current vision and assumptions of the management
of the Company. They incorporate known and unknown risks and
uncertainties that could result in significant differences in
results, profitability and expected events. In addition, Eurobio
Scientific, its shareholders and its affiliates, directors,
officers, counsels and employees have not verified the accuracy of,
and make no representations or warranties about, statistical
information or forecast information contained within this news
release and that originates or is derived from third party sources
or industry publications; these statistical data and forecast
information are only used in this press release for information
purposes. Finally, this press release may be drafted in French and
in English. In the event of differences between the two texts, the
French version will prevail.
1 https://covid-19.sante.gouv.fr/tests
2 Also called neutralizing antibody tests, or protective
immunity tests
- 210118_Eurobio_antigene_EN
Grafico Azioni Eurobio Scientific (EU:ALERS)
Storico
Da Feb 2024 a Mar 2024
Grafico Azioni Eurobio Scientific (EU:ALERS)
Storico
Da Mar 2023 a Mar 2024